Financial Performance - For the six months ended September 30, 2024, the company's revenue was approximately HKD 57.9 million, a decrease of about HKD 208,000 compared to the same period in 2023[5]. - The net loss attributable to owners of the company for the period was approximately HKD 916,000, compared to a net loss of approximately HKD 2.3 million for the same period in 2023[5]. - Total comprehensive loss for the six months ended September 30, 2024, was HKD 984,000, compared to HKD 2.3 million for the same period in 2023[9]. - Basic and diluted loss per share for the period was HKD 2.202, compared to HKD 5.457 for the same period in 2023[9]. - Total revenue for the six months ended September 30, 2024, was HKD 61,830,000, a decrease from HKD 58,083,000 for the same period in 2023[39]. - The company reported a pre-tax loss of HKD 2,283,000 for the six months ended September 30, 2024, compared to a pre-tax loss of HKD 737,000 for the same period in 2023[45]. - Basic loss per share for the six months ended September 30, 2024, was HKD (916), compared to HKD (2,270) for the same period in 2023[50]. - The company experienced a loss from operations of HKD (1,127,000) for the six months ended September 30, 2024, compared to a profit of HKD 501,000 in the previous year[39]. Revenue Breakdown - The external revenue from dental services was HKD 26,791,000, while medical services generated HKD 31,292,000 for the six months ended September 30, 2024[39]. - Revenue from providing medical solutions to corporate clients increased by approximately 9.5% to HKD 20.9 million from HKD 19.1 million in the previous period[69]. - Revenue from self-paying patients for medical services increased by approximately 5.5% to HKD 12.8 million from HKD 12.2 million in the previous period[70]. - Revenue from providing dental solutions to corporate clients increased by approximately 28.2% to HKD 2.3 million from HKD 1.8 million in the previous period[70]. - Revenue from self-paying patients for dental services decreased by approximately 12.8% to HKD 21.8 million from HKD 25.0 million in the previous period[70]. - Revenue from medical plans for insurance companies was HKD 14,767,000, slightly down from HKD 15,152,000 in the previous year[42]. Assets and Liabilities - As of September 30, 2024, total assets amounted to HKD 15,390 million, an increase from HKD 12,777 million as of March 31, 2024, representing a growth of approximately 20.5%[10]. - Total current liabilities increased to HKD 37,595 million as of September 30, 2024, up from HKD 35,771 million as of March 31, 2024, reflecting a rise of 5.1%[10]. - The company’s non-current liabilities, specifically lease liabilities, increased to HKD 4,514 million as of September 30, 2024, from HKD 2,802 million as of March 31, 2024, marking a rise of 60.9%[12]. - The total equity attributable to owners of the company decreased to HKD 2,648 million as of September 30, 2024, down from HKD 3,632 million as of March 31, 2024, a decline of 27.1%[15]. - The company’s total liabilities increased to HKD 37,595 million as of September 30, 2024, compared to HKD 35,771 million as of March 31, 2024, reflecting a growth of 5.1%[10]. Cash Flow - The company reported a net cash inflow from operating activities of HKD 2,107 million for the six months ended September 30, 2024, compared to HKD 770 million for the same period in 2023, indicating a significant increase of 173.5%[19]. - The company’s cash and cash equivalents decreased to HKD 15,009 million as of September 30, 2024, down from HKD 17,325 million as of March 31, 2024, a decline of 13.4%[19]. - The net cash used in financing activities was HKD 4,374 million for the six months ended September 30, 2024, compared to a net cash inflow of HKD 4,848 million for the same period in 2023[19]. Operational Highlights - The company incurred total employee costs of HKD 18,727,000 for the six months ended September 30, 2024, an increase from HKD 17,586,000 in the previous year[45]. - Employee costs increased by approximately 6.5% to HKD 18.7 million from HKD 17.6 million in the previous period, mainly due to an increase in the number of employees and annual salary adjustments[74]. - The company spent approximately HKD 134,000 on the purchase of property, plant, and equipment during the period, significantly lower than HKD 1,329,000 for the six months ended September 30, 2023[51]. - Medical and dental professional service expenses slightly decreased by 1.0% to approximately HKD 25.0 million from HKD 25.3 million in the previous period[73]. - Cost of medical and dental supplies significantly reduced by approximately 29.4% from about HKD 5.1 million to approximately HKD 3.6 million[76]. - Other expenses decreased by approximately 13.1% from about HKD 7.2 million to approximately HKD 6.2 million, primarily due to cost control measures[79]. Corporate Governance - The board of directors does not recommend the payment of an interim dividend for the period[5]. - The Audit Committee was established on May 19, 2016, in accordance with GEM Listing Rules, consisting of three independent non-executive directors[112]. - The Audit Committee's main responsibilities include reviewing and supervising internal controls and risk management systems[112]. - The executive directors as of the announcement date are Mr. Chan Chi Wai and Ms. Jiang Jie, with independent non-executive directors including Mr. Leung Po Han, Mr. Wong Wai Leung, and Mr. Ng Wai Hung[114]. Shareholder Information - The issued share capital of the company as of September 30, 2024, was HKD 10,400,000, with 41,600,000 shares outstanding[83]. - As of September 30, 2024, Medinet International Limited holds 23,400,000 shares, representing 56.25% of the company's issued share capital[99]. - NSD Capital Limited, Convoy Asset Management Limited, Favour Sino Holdings Limited, and Convoy (BVI) Limited each hold 7,800,000 shares, accounting for 18.75% of the company's issued share capital[99]. - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[104].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本 公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 MediNet Group Limited 醫匯集團有限公司 公司秘書 梁文輝 香港，2024年11月12日 於本公告日期，執行董事為陳志偉先生及姜洁女士，獨立非執行董事為梁寶漢先 生，黃偉樑先生及吳偉雄先生。 本公告遵照聯交所GEM證券上市規則的規定，提供關於本公司的資料；董事共同 及 個 別 對 本 公 告 負 全 責 。 董 事 經 作 出 一 切 合 理 查 詢 後 確 認 ， 據 彼 等 所 深 知 及 確 信，本公告所載資料在所有重大方面均屬準確及完整，並無誤導或欺詐成份，且 並無遺漏任何其他事宜導致本公告或當中任何聲明有誤導成份。 本公告將由其刊登日期起最少七日於聯交所網站www.hkexnews.hk（ 就公告而言， 於「最新公司公告」網頁 ）登載。本公告亦將於本公司網站www.Medi Net Group.com 登載。 醫 匯 集 團 有 限 公 司 （於開曼群島註冊 ...

Financial Performance - The group's revenue for the fiscal year ending March 31, 2024, was approximately HKD 116.2 million, an increase of about 5.3% from HKD 110.4 million in the previous fiscal year[14]. - The loss attributable to the owners of the company for the fiscal year 2023/24 was approximately HKD 8.1 million, a significant reduction from HKD 24.9 million in the fiscal year 2022/23[14]. - Revenue from medical solutions provided to contract clients increased by 45.7%, from approximately HKD 27.7 million to HKD 40.4 million[15]. - Revenue from self-paying patients for medical services rose by 43.6%, from approximately HKD 17.5 million to HKD 25.2 million[15]. - Revenue from dental solutions provided to contract clients decreased by 22.3%, from approximately HKD 7.1 million to HKD 5.5 million[15]. - Revenue from self-paying patients for dental services also saw a decline of 22.2%, from approximately HKD 58.0 million to HKD 45.2 million[15]. - Other income decreased from approximately HKD 3.5 million in FY2022/23 to approximately HKD 561,000 in FY2023/24, mainly due to the absence of additional income from the Hong Kong government's employment support scheme[19]. - Medical and dental professional service expenses increased from approximately HKD 42.9 million in FY2022/23 to approximately HKD 50.3 million in FY2023/24, an increase of about 17.2%, consistent with the revenue growth[21]. - Employee costs slightly decreased from approximately HKD 37.8 million in FY2022/23 to approximately HKD 37.2 million in FY2023/24, a decline of about 1.6% due to a decrease in average employee salary levels[22]. - The company incurred financing costs of HKD 660,000, up from HKD 560,000, reflecting increased borrowing[199]. - Other income decreased significantly to HKD 561,000 from HKD 3,539,000, a decline of 84.1%[199]. Corporate Governance - The company emphasizes the importance of good corporate governance for long-term success and sustainable development[65]. - The board is committed to maintaining high corporate governance standards to enhance accountability and transparency, protecting shareholder interests[66]. - The company has adhered to the corporate governance code throughout the fiscal year ending March 31, 2024, with one exception regarding the separation of roles between the chairman and CEO[68]. - The company aims to provide satisfactory and sustainable returns to shareholders while managing overall business risks appropriately[67]. - The company has established a corporate governance framework and developed a series of policies and procedures to enhance governance practices[66]. - The board believes that the current structure of having the same individual serve as chairman and CEO is beneficial for implementing business strategies[68]. - The company will regularly review and improve its corporate governance practices in line with the latest developments[69]. - The board currently consists of five directors, including two executive directors and three independent non-executive directors[71]. - The board has complied with GEM listing rules by appointing at least three independent non-executive directors, representing at least one-third of the board[73]. - All independent non-executive directors have confirmed their independence in writing prior to their appointment[73]. - The board held a total of four meetings during the year, with all directors actively participating[79]. - The chairman, Mr. Chan, attended all board meetings and the annual general meeting[79]. - The company has adopted a standard code for regulating directors' securities transactions, ensuring compliance with GEM listing rules[78]. - The nomination committee is responsible for reviewing the board composition and evaluating the independence of non-executive directors[74]. - The board has established a governance policy and is satisfied with its performance[72]. - The company has established a governance framework with three committees: Audit Committee, Nomination Committee, and Remuneration Committee, primarily composed of independent non-executive directors[90]. - The Audit Committee is responsible for reviewing financial controls, internal monitoring, and risk management systems, ensuring adequate disclosure in financial reporting[93]. - The company has a policy in place to ensure board member diversity, considering various factors such as gender, age, and professional experience[86]. - The company’s chairman and CEO roles are held by the same individual, which the board believes provides strong and consistent leadership[84]. Shareholder Communication - The company has established a shareholder communication policy to ensure shareholder opinions and concerns are properly addressed[127]. - The company encourages shareholders to participate in annual general meetings and allows for proxy voting if they cannot attend[131]. - The company maintains effective communication with investors to enhance transparency and understanding of its business and developments[133]. - The company has multiple channels for ongoing communication with shareholders, including company announcements and its website[128]. Financial Position - The total assets of the group as of March 31, 2024, were approximately HKD 42.0 million, compared to approximately HKD 42.9 million in 2023[31]. - The current ratio as of March 31, 2024, was approximately 0.8 times, compared to approximately 0.9 times in 2023[32]. - The company has a distributable reserve of approximately HKD 3.6 million as of March 31, 2024[152]. - The company has no significant contingent liabilities, legal disputes, or potential lawsuits as of March 31, 2024[146]. - The company’s asset-liability ratio as of March 31, 2024, is approximately 4.39, a significant increase from 0.84 in 2023[149]. - The company has no assets pledged as collateral as of March 31, 2024[158]. - The company has sufficient financial resources to continue operations for the foreseeable future, adopting a "going concern" basis in preparing its consolidated financial statements[147]. - The company has no significant or material disputes with stakeholders in the 2023/24 fiscal year[140]. - The independent auditor's report confirms that the consolidated financial statements fairly reflect the group's financial position as of March 31, 2024[179]. Management and Leadership - Mr. Chan has over 35 years of experience in the corporate medical and dental solutions industry, having founded the group in 1994[46]. - Ms. Jiang has accumulated over 10 years of experience in business development and customer relationship management since joining the group in 2009[48]. - The company is focused on strategic planning and compliance under the leadership of its executive directors[46]. - The company has appointed Mr. Wu as a non-executive director of Luchai Culture Limited (formerly known as Jingji Smart Culture Holdings) since September 2023[59]. - The company has no internal audit department but will continue to assess the need for one annually, considering the cost-effectiveness of hiring external professionals[112]. - The company is committed to anti-corruption and anti-bribery initiatives, actively organizing training and investigations to foster a culture of integrity[112]. Revenue Recognition and Audit - The independent auditor's report emphasizes the importance of revenue recognition as a key audit matter due to the volume of transactions recorded in the business system[183]. - The auditor's procedures included testing the effectiveness of controls over data transfer from operational systems to the accounting system, ensuring the accuracy of recorded transactions[185]. - The company engaged an independent external valuer to assist in the valuation of goodwill, ensuring objectivity in the assessment process[184]. Future Outlook - The company aims to maintain close relationships with existing clients while exploring new business opportunities[9]. - Future focus will remain on providing medical and dental services to corporate clients and the general public[10]. - The company plans to enhance internal controls and address identified deficiencies to improve financial reporting and compliance[196].

Financial Performance - For the fiscal year ending March 31, 2024, the company's revenue was approximately HKD 116.2 million, an increase of about HKD 5.8 million or 5.3% compared to the fiscal year ending March 31, 2023[9]. - The company's loss attributable to owners decreased from approximately HKD 24.9 million for the year ending March 31, 2023, to approximately HKD 8.1 million for the year ending March 31, 2024[9]. - Total revenue for the year ended March 31, 2024, was HKD 3,116,248,000, an increase from HKD 110,392,000 in 2023[10]. - The company reported a loss before tax of HKD 7,999,000, significantly improved from a loss of HKD 25,463,000 in 2023[10]. - Net loss for the year was HKD 8,104,000, compared to a loss of HKD 25,150,000 in the prior year[10]. - Basic loss per share improved to HKD 19.43 from HKD 59.81 in the previous year[10]. - Total comprehensive loss for the year was HKD 8,148,000, down from HKD 25,309,000 in 2023[10]. - The company reported a pre-tax loss of HKD 7,999,000, indicating challenges in profitability during the reporting period[46]. - The company reported a pre-tax loss of HKD 25,463,000 for the period[48]. Revenue Breakdown - Total revenue for the year ending March 31, 2024, reached HKD 116,248,000, with dental business contributing HKD 50,711,000 and medical business contributing HKD 65,537,000[31]. - Revenue from dental services amounted to HKD 45,186,000, while revenue from medical services totaled HKD 25,176,000[31]. - The company generated HKD 30,197,000 from solutions provided to insurance companies and HKD 10,164,000 from solutions provided to enterprises within the medical business segment[31]. - Revenue recognized at a specific point in time was HKD 85,423,000, while revenue recognized over a period amounted to HKD 30,825,000[31]. - The company reported a total of HKD 115,919,000 in revenue from the Hong Kong market, with HKD 329,000 from the China market[31]. - Total revenue for the period ending March 31, 2023, was HKD 110,392,000, with dental services contributing HKD 65,161,000 and medical services contributing HKD 45,231,000[33]. - The dental solutions segment generated HKD 58,048,000 from services, while the medical solutions segment generated HKD 19,717,000 from insurance companies and HKD 7,981,000 from corporate clients[33]. Expenses and Costs - The company experienced a decrease in medical and dental service costs to HKD 50,262,000 from HKD 42,860,000[10]. - Employee costs were reduced to HKD 37,227,000 from HKD 37,793,000[10]. - Rental expenses decreased to HKD 912,000 from HKD 1,866,000[10]. - The company reported a significant reduction in other operating expenses to HKD 13,983,000 from HKD 14,249,000[10]. - Medical and dental professional service expenses increased from approximately HKD 42.9 million in FY2022/23 to about HKD 50.3 million in FY2023/24, representing a growth of approximately 17.2%[80]. - Employee costs slightly decreased from approximately HKD 37.8 million in FY2022/23 to about HKD 37.2 million in FY2023/24, a reduction of approximately 1.6%[81]. - Depreciation of property, plant, and equipment decreased from approximately HKD 2.3 million in FY2022/23 to about HKD 1.7 million in FY2023/24, a decline of approximately 26.1%[82]. - Medical and dental supplies costs decreased by approximately 13.0% from about HKD 10.8 million in FY2022/23 to approximately HKD 9.4 million in FY2023/24[84]. - Rental expenses decreased from approximately HKD 1.9 million in FY2022/23 to about HKD 0.9 million in FY2023/24, a reduction of approximately HKD 1.0 million[85]. - Other expenses slightly decreased from approximately HKD 14.2 million in FY2022/23 to about HKD 14.0 million in FY2023/24, a reduction of approximately 1.4%[86]. Assets and Liabilities - Total assets decreased from HKD 15,189 million in 2023 to HKD 6,255 million in 2024, indicating a significant reduction in net assets[11]. - Current liabilities increased from HKD 27,686 million in 2023 to HKD 35,771 million in 2024, reflecting a rise of approximately 29.2%[12]. - Cash and cash equivalents rose from HKD 15,574 million in 2023 to HKD 17,325 million in 2024, showing an increase of about 11.3%[11]. - Accounts receivable increased from HKD 8,875 million in 2023 to HKD 10,679 million in 2024, representing a growth of approximately 20.3%[11]. - The company reported a net current liability of HKD (6,522) million in 2024, compared to HKD (2,395) million in 2023, indicating a worsening liquidity position[11]. - The total non-current liabilities decreased from HKD 3,860 million in 2023 to HKD 3,074 million in 2024, a decline of about 20.3%[12]. - The company’s equity attributable to owners decreased from HKD 3,632 million in 2023 to HKD 11,758 million in 2024, reflecting a significant change in ownership equity[12]. - The company’s total liabilities increased from HKD 27,686 million in 2023 to HKD 35,771 million in 2024, marking an increase of approximately 29.2%[12]. - The company’s fixed assets decreased from HKD 17,584 million in 2023 to HKD 12,777 million in 2024, indicating a reduction of about 27.8%[11]. - The company’s goodwill decreased from HKD 1,905 million in 2023 to HKD 0 in 2024, indicating a complete write-off of goodwill[11]. Accounting Standards and Compliance - The group has adopted new Hong Kong Financial Reporting Standards (HKFRS) effective from April 1, 2023, with no significant impact on the financial position and performance[17]. - The application of the revised HKFRS 8 clarifies the definition of accounting estimates, focusing on monetary amounts with measurement uncertainty[19]. - The group has implemented the revised HKFRS 12, narrowing the scope of deferred tax liabilities and assets recognition exemptions, effective for transactions occurring after April 1, 2022[20]. - The revised HKFRS 1 and HKFRS Practice Statement 2 have been applied, replacing "significant accounting policy information" with "material accounting policy information" in financial statements[21]. - The revisions to HKFRS Practice Statement 2 provide guidance on applying the "four-step process for assessing materiality" in accounting policy disclosures[24]. - The company anticipates the application of new Hong Kong Financial Reporting Standards and amendments will not have a significant impact on consolidated financial statements in the foreseeable future[26]. - The company expects to apply all other new Hong Kong Financial Reporting Standards and amendments in the future without significant impact on financial reporting[26]. Market and Operational Insights - The company operates six dental clinics and two medical centers in Hong Kong, along with one dental clinic in Shenzhen[72]. - The company provides dental solutions through annual prepaid contracts, allowing clients to access various dental services at predetermined prices[35]. - Medical solutions are also offered through annual prepaid contracts, which include services such as general practitioner consultations and health check-ups[40]. - The company emphasizes its commitment to fulfilling contractual obligations to clients, ensuring that services are delivered as promised[36]. - The dental services segment includes a range of treatments such as orthodontics, dental implants, and routine check-ups[37]. - The medical solutions segment includes comprehensive healthcare services, ensuring clients receive necessary medical attention throughout the contract period[40]. - The group categorizes its business segments into dental solutions and services, and medical solutions and services, with a focus on resource allocation and performance evaluation[45]. - The company aims to enhance its market position through strategic investments and operational improvements in both dental and medical segments[46]. - Future outlook includes a focus on expanding user data and leveraging new technologies to drive growth[46]. Shareholder and Governance Matters - The board of directors does not recommend the payment of any dividends for the fiscal year ending March 31, 2024[9]. - The company does not recommend any dividend payment for the year ending March 31, 2024, consistent with the previous year[56]. - The annual general meeting of shareholders is scheduled for August 9, 2024, with a suspension of share registration from August 6 to August 9, 2024[105]. - The audit committee held four meetings during the fiscal year 2023/24 to review and approve financial reporting matters[113]. - There have been no significant events occurring after March 31, 2024, up to the date of this announcement[114]. - The company emphasized the importance of adhering to accounting standards and GEM listing rules during the review of quarterly, semi-annual, and annual financial statements[118]. - Internal control systems effectiveness was discussed, focusing on financial, operational, compliance controls, and risk management[118].

Financial Performance - The group's revenue for the six months ended September 30, 2023, was approximately HKD 58.1 million, a decrease of about HKD 0.6 million compared to the same period in 2022[8]. - The net loss attributable to the owners of the company for the six months ended September 30, 2023, was approximately HKD 2.3 million, compared to a net loss of approximately HKD 45,000 in the same period of 2022[8]. - Total comprehensive loss for the period amounted to HKD 2.32 million, compared to a total comprehensive income of HKD 212,000 in the same period of 2022[15]. - Basic and diluted loss per share for the period was HKD 5.457, compared to HKD 0.107 in the same period of 2022[15]. - The group reported a loss before tax of HKD 2,283,000 for the six months ended September 30, 2023, compared to a loss of HKD 187,000 in the same period last year[42]. - The company reported a loss of HKD 2,270 thousand for the period, compared to a loss of HKD 45 thousand in the same period last year[21]. Revenue Breakdown - Total revenue for the six months ended September 30, 2023, was HKD 58,083,000, a decrease of 1.1% compared to HKD 58,723,000 for the same period in 2022[35]. - Dental service revenue from contract clients (mainly enterprises and insurance companies) was HKD 19,119,000, up 41.5% from HKD 13,485,000 in the previous year[39]. - Revenue from dental services provided to self-paying patients was HKD 24,992,000, down 27.8% from HKD 34,617,000 in the previous year[39]. - Revenue from medical solutions provided to contract clients increased by 41.8% to approximately HKD 19.1 million, driven by an increase in consultation frequency[64]. - Revenue from self-paying patients for medical services rose by 43.5% to approximately HKD 12.2 million, mainly due to increased demand for medical consultation services[64]. - Revenue from dental solutions provided to contract clients decreased by 15.9% to approximately HKD 1.8 million, attributed to a reduction in the number of contract clients[64]. - Revenue from self-paying patients for dental services fell by 27.8% to approximately HKD 25.0 million, primarily due to a decrease in the number of patients seeking follow-up dental services[64]. Expenses and Costs - Medical and dental professional service expenses increased to HKD 25.269 million from HKD 21.463 million year-on-year[14]. - Employee costs decreased to HKD 17.586 million from HKD 18.762 million year-on-year[14]. - The group incurred total employee costs of HKD 17,586,000, a decrease from HKD 18,762,000 in the previous year[42]. - Medical and dental professional service expenses increased by 17.7% to approximately HKD 25.3 million, due to higher payments to network doctors and third-party laboratories[66]. - Employee costs decreased by approximately 6.4% to HKD 17.6 million, primarily due to a reduction in the number of employees[68]. Assets and Liabilities - As of September 30, 2023, total assets amounted to HKD 48,798 thousand, an increase from HKD 42,875 thousand as of March 31, 2023, reflecting a growth of approximately 13.9%[17]. - Total liabilities increased to HKD 36,801 thousand as of September 30, 2023, compared to HKD 27,686 thousand as of March 31, 2023, indicating a rise of approximately 33.0%[19]. - The company's net asset value decreased to HKD 9,007 thousand from HKD 11,329 thousand, a decline of about 20.5%[19]. - The total amount of accounts receivable and other receivables increased to HKD 12,711,000 as of September 30, 2023, from HKD 10,355,000 as of March 31, 2023, representing a growth of approximately 21.3%[49]. - The total accounts payable increased to HKD 14,706,000 as of September 30, 2023, from HKD 13,515,000 as of March 31, 2023, reflecting an increase of approximately 8.8%[52]. Cash Flow and Financing - The company's cash and cash equivalents increased to HKD 19,946 thousand from HKD 15,574 thousand, representing a growth of 28.5%[22]. - The net cash generated from operating activities for the six months ended September 30, 2023, was HKD 770 thousand, a significant decrease from HKD 8,817 thousand in the same period of 2022[22]. - The company raised new bank loans amounting to HKD 9,000 thousand during the financing activities[22]. - The company raised new bank borrowings of HKD 9,000,000 during the six months ended September 30, 2023, compared to no new borrowings in the same period of 2022[55]. Corporate Governance - The board of directors did not recommend the payment of an interim dividend for the six months ended September 30, 2023[8]. - The company did not declare any interim dividend for the six months ended September 30, 2023, consistent with the same period in 2022[45]. - The board is committed to maintaining high standards of corporate governance, which is essential for protecting shareholder interests and enhancing corporate value[93]. - The company has adopted the corporate governance code as per GEM Listing Rules Appendix 15, establishing a framework for governance practices[93]. - The company has complied with the corporate governance code, except for the deviation in clause C.2.1, which states that the roles of Chairman and CEO should be separated[95]. - The audit committee has reviewed the unaudited condensed consolidated financial statements for the six months ended September 30, 2023[102]. - The audit committee consists of three independent non-executive directors, with Mr. Leung Po-Hon serving as the chairman[101]. Employee Information - As of September 30, 2023, the group had a total of 89 employees, down from 100 employees as of September 30, 2022[83]. - The company’s short-term employee benefits for key management personnel amounted to HKD 3,342,000 for the period, slightly down from HKD 3,386,000 in the previous year[59]. - The company’s employee compensation is reviewed annually based on performance assessments and market competitiveness[83].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本 公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確 表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 MediNet Group Limited 醫 匯 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8161） 截 至2023年9月30日 止 六 個 月 的 中 期 業 績 公 告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的 定 位 乃 為 相 比 起 聯 交 所 上 市 的 其 他 公 司 帶 有 更 高 投 資 風 險 的 中 小型公司提供上市的市場。有意投資者應了解投資於此類公司的潛在風險， 並應經審慎周詳考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會承受較 於聯交所主板買賣的證券為高的市場波動風險，同時亦無法保證在GEM 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或 任何部分內容而產生或因倚 ...

Financial Performance - The group's revenue for the three months ended June 30, 2023, was approximately HKD 29.1 million, an increase of about HKD 0.7 million compared to HKD 28.4 million for the same period in 2022[5]. - The net loss attributable to the company's owners for the period was approximately HKD 960,000, compared to a net profit of approximately HKD 105,000 for the same period in 2022[5]. - The total comprehensive loss for the period was HKD 407,000, compared to a total comprehensive income of HKD 329,000 for the same period in 2022[9]. - The basic loss per share for the period was HKD (2.30), compared to earnings per share of HKD 0.25 for the same period last year[9]. - Revenue for the three months ended June 30, 2023, increased by approximately 2.6% to HKD 29.1 million from HKD 28.4 million for the same period in 2022[26]. - The increase in net loss was primarily due to the absence of a HKD 688,000 subsidy from the Hong Kong government under the "Employment Support" scheme in 2022[24]. Revenue Sources - Revenue from medical services provided to contract clients rose by 57.8% to HKD 10.2 million, up from HKD 6.5 million in the previous year[26]. - Revenue from self-paying patients for medical services increased by 36.5% to HKD 5.5 million, compared to HKD 4.1 million in the prior year[27]. - Revenue from contract clients for dental solutions increased by approximately HKD 120,000, primarily due to an increase in the number of contract clients and individual patients[29]. - Revenue from self-paying patients for dental services decreased from approximately HKD 16.5 million to about HKD 11.9 million, a decline of approximately 27.9%, mainly due to a reduction in patient visits[29]. Expenses - Medical and dental professional service expenses increased to HKD 13.2 million from HKD 11.6 million year-on-year[9]. - The company's other income decreased to HKD 178,000 from HKD 861,000 in the previous year[9]. - Employee costs decreased to HKD 8.6 million from HKD 9.1 million compared to the same period last year[9]. - Other expenses increased by approximately 71.4% from about HKD 2.1 million to approximately HKD 3.6 million, mainly due to increased marketing expenses and the reopening of clinics after lease expirations[38]. - Medical and dental supplies costs decreased by approximately 8.7% from about HKD 2.3 million to approximately HKD 2.1 million, mainly due to a reduction in the quantity of other medical and dental consumables[35]. - Medical and dental professional service expenses rose from approximately HKD 11.6 million in 2022 to about HKD 13.2 million in the current period[24]. - Employee costs decreased by approximately 5.5% from about HKD 9.1 million to approximately HKD 8.6 million, primarily due to a reduction in the number of employees in Hong Kong and mainland China[33]. Dividends and Shareholder Information - The board of directors did not recommend the payment of an interim dividend for the three months ended June 30, 2023[6]. - The company did not propose any interim dividend for the three months ended June 30, 2023[56]. - As of June 30, 2023, Medinet International Limited holds 23,400,000 shares, representing 56.25% of the company's issued share capital[47]. - NSD Capital Limited, Convoy Asset Management Limited, Favour Sino Holdings Limited, Convoy (BVI) Limited, and 康宏環球控股有限公司 each hold 7,800,000 shares, accounting for 18.75% of the company's issued share capital[47]. Corporate Governance - The board confirmed compliance with the GEM Listing Rules regarding securities trading standards for all directors during the three months ended June 30, 2023[55]. - The audit committee reviewed the unaudited condensed consolidated financial statements for the three months ended June 30, 2023[57]. - The company did not purchase, sell, or redeem any of its listed securities during the three months ended June 30, 2023[52]. - There were no known business or interest conflicts involving directors or major shareholders as of June 30, 2023[51]. - The company has adopted a code of conduct for directors' securities transactions, ensuring adherence to trading standards[55]. - The chairman and CEO roles are currently held by the same individual, which the board believes enhances strategic efficiency[53]. - The company has established an audit committee to oversee financial reporting and risk management processes[57].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本 公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確 表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 MediNet Group Limited 醫 匯 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8161） 截 至2023年6月30日 止 三 個 月 的 第 一 季 度 業 績 公 告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的 定 位 乃 為 相 比 起 聯 交 所 上 市 的 其 他 公 司 帶 有 更 高 投 資 風 險 的 中 小型公司提供上市的市場。有意投資者應了解投資於此類公司的潛在風險， 並應經審慎周詳考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會承受較 於聯交所主板買賣的證券為高的市場波動風險，同時亦無法保證在GEM 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或 任何部分內容而產 ...

Financial Performance - The group's revenue for the fiscal year 2022/23 was approximately HKD 110.4 million, a decrease of about 8.8% or HKD 10.7 million compared to HKD 121.1 million in 2021/22[15]. - The loss attributable to the company's owners for the fiscal year 2022/23 was approximately HKD 24.9 million, compared to a loss of HKD 6.2 million in 2021/22, primarily due to impairment losses on goodwill[15]. - Revenue from medical solutions provided to contract clients fell from approximately HKD 29.3 million to approximately HKD 27.7 million, a decrease of about 5.6%[18]. - Revenue from dental solutions provided to contract clients increased from approximately HKD 6.3 million to approximately HKD 7.1 million, an increase of about 12.5%[18]. - Other income rose significantly from approximately HKD 1.2 million to approximately HKD 3.5 million, mainly due to additional income from the Hong Kong government's employment support scheme of about HKD 2.0 million[19]. - Other losses increased from approximately HKD 138,000 to approximately HKD 17.9 million, primarily due to the recognition of goodwill impairment loss of about HKD 17.6 million in the fiscal year 2022/23[20]. - Employee costs for the fiscal year 2022/23 were approximately HKD 37.8 million, down from HKD 42.5 million in 2021/22, representing a decrease of about 16.5%[46]. - The group's total assets as of March 31, 2023, were approximately HKD 42.9 million, down from approximately HKD 68.5 million in 2022[31]. - The current ratio as of March 31, 2023, was approximately 0.9 times, compared to approximately 1.0 times in 2022[32]. - The company reported a total reserve available for distribution to shareholders of approximately HKD 3.1 million as of March 31, 2023[156]. Business Operations - Patient visit rates began to improve gradually in March 2023 following the lifting of COVID-19 social distancing restrictions and the reopening of borders between Hong Kong and China[15]. - The company aims to continue focusing on providing medical and dental services to corporate clients and the general public in the future[12]. - Management is committed to enhancing business development efforts and expanding revenue sources while managing expenses prudently[15]. - The company operates six dental clinics, two medical centers, and one genetic testing center in Hong Kong, as well as one dental clinic in Shenzhen[15]. - The overall economic activity has started to recover gradually during the year, despite the ongoing impact of the COVID-19 pandemic[9]. - The company has been actively exploring business opportunities to broaden its revenue sources while maintaining close relationships with existing clients[10]. - The management team expresses confidence that business will regain momentum as the pandemic is brought under control and all COVID-19 restrictions are lifted[11]. Corporate Governance - The board of directors consists of five members, including two executive directors and three independent non-executive directors, responsible for overseeing business operations and financial planning[52]. - The company emphasizes the importance of good corporate governance for long-term success and sustainable development[68]. - The board is committed to maintaining high corporate governance standards to protect shareholder interests and enhance corporate value[69]. - The company has adhered to the corporate governance code throughout the fiscal year ending March 31, 2023, with one exception regarding the separation of roles between the chairman and CEO[71]. - The management team has over 25 years of operational experience within the company, ensuring effective implementation of business strategies[65]. - The company has established a corporate governance framework and a series of policies and procedures to enhance governance and oversight[70]. - The company will regularly review and improve its corporate governance practices in line with the latest developments[72]. - The board has established a governance policy and is satisfied with its performance[75]. - The company has adopted a standard code for securities trading for directors, ensuring compliance with GEM listing rules[81]. - The nomination committee is responsible for reviewing board composition and assessing the independence of non-executive directors[77]. Risk Management - The company faces various risks, including strategic, reputational, and compliance risks, which could adversely affect its financial performance and business outlook[47][49][50]. - The Audit Committee is responsible for overseeing financial controls and risk management systems[96]. - The company has implemented controls to ensure the accuracy of data transferred from operational systems to accounting systems[195]. - The management's assessment of the recoverable amounts of assets involved significant judgment and estimation[196]. - The company will continue to hire independent professionals annually to review its internal control and risk management systems[114]. Shareholder Communication - The company has established a shareholder communication policy to ensure shareholder opinions and concerns are properly addressed[130]. - The company has maintained effective communication with shareholders through various channels, including annual general meetings and company announcements[131]. - Shareholders have the right to submit proposals for consideration at the annual general meeting, subject to verification by the company’s share transfer office[126]. - The company encourages investors to share their opinions and inquiries through its website and direct communication channels[137]. Environmental Responsibility - The company emphasizes environmental responsibility by encouraging resource conservation and recycling among employees[143]. Financial Compliance - The company has maintained compliance with the Securities and Futures Ordinance and GEM Listing Rules during the fiscal year 2022/23[148]. - The independent auditor's report confirms that the consolidated financial statements fairly reflect the company's financial position as of March 31, 2023[189]. - The company has no significant related party transactions that require disclosure under the GEM Listing Rules[180]. - The company has no provisions for preemptive rights for existing shareholders regarding the issuance of new shares, except as required by the stock exchange[185]. Employee Management - The total number of employees decreased from 114 in 2022 to 112 in 2023, with a notable reduction in employed and contracted dentists from 19 to 18[45]. - Employee costs decreased from approximately HKD 42.5 million to approximately HKD 37.8 million, a reduction of about 11.1% due to a decrease in the number of employees[22]. Audit and Financial Oversight - The Audit Committee held 5 meetings in the 2022/23 fiscal year to review financial statements and internal control systems[98]. - The Nomination Committee held 1 meeting in the 2022/23 fiscal year to assess board diversity and the performance of directors[100]. - The Remuneration Committee held 1 meeting in the 2022/23 fiscal year to review the compensation of directors and senior management[104].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 MediNet Group Limited 醫 匯 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8161） 截 至2023年3月31日 止 年 度 年 度 業 績 公 告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的 定 位，乃 為 中 小 型 公 司 提 供 一 個 上 市 的 市 場，此 等 公 司 相 比 起 其 他在聯交所上市的公司帶有較高投資風險。有意投資者應了解投資於此 類公司的潛在風險，並應經審慎周詳考慮後方作出投資決定。 由於GEM上市的公司普遍為中小型公司，在GEM買賣的證券可能會承受 較 於 聯 交 所 主 板 買 賣 的 證 券 為 高 的 市 場 波 動 風 險，同 時 亦 無 法 保 證 在 GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概 ...